Researchers are excitedly investigating retatrutide, a innovative treatment created by Eli Lilly, as a possible advance in physique loss . Unlike many earlier approaches, retatrutide is a dual -action compound targeting both GLP-1 and GIP, substances that impact hunger and glucose balance. Early